tiprankstipranks
Advertisement
Advertisement

ALPMF Stock Latest News

Astellas Extends Global Performance-Linked Stock Incentives for Executives
Company AnnouncementsAstellas Extends Global Performance-Linked Stock Incentives for Executives
7d ago
Astellas Extends Performance-Linked Stock Incentive Plan for Directors in FY2026
PremiumCompany Announcements
Astellas Extends Performance-Linked Stock Incentive Plan for Directors in FY2026
7d ago
Astellas Rated Hold as Xtandi Headwinds Offset Pipeline Potential; Price Target Reiterated at ¥2,200
PremiumRatings
Astellas Rated Hold as Xtandi Headwinds Offset Pipeline Potential; Price Target Reiterated at ¥2,200
10d ago
Astellas Books Major Impairment and Extraordinary Losses in FY2025 Non-Consolidated Results
PremiumCompany Announcements
Astellas Books Major Impairment and Extraordinary Losses in FY2025 Non-Consolidated Results
25d ago
Astellas Pharma Announces New Board Slate and Governance Changes for 2026
PremiumCompany Announcements
Astellas Pharma Announces New Board Slate and Governance Changes for 2026
25d ago
Is ALPMF a Buy, Before Earnings?
PremiumPre-EarningsIs ALPMF a Buy, Before Earnings?
27d ago
Astellas’ Menopause Drug Fezolinetant Hits Key Safety Milestone in Japan
Premium
Company Announcements
Astellas’ Menopause Drug Fezolinetant Hits Key Safety Milestone in Japan
1M ago
ALPMF
Astellas Highlights R&D Strategy While Flagging Market and Development Risks
Premium
Company Announcements
Astellas Highlights R&D Strategy While Flagging Market and Development Risks
2M ago
Astellas and HOVON Phase 3 AML Trial for Xospata Misses Survival Goal
PremiumCompany Announcements
Astellas and HOVON Phase 3 AML Trial for Xospata Misses Survival Goal
2M ago
Astellas Flags Risks and Uncertainties Around Sustainability Plans and Pipeline
PremiumCompany Announcements
Astellas Flags Risks and Uncertainties Around Sustainability Plans and Pipeline
3M ago
Why Is Vir Biotechnology Stock Up Today?
PremiumMarket News
Why Is Vir Biotechnology Stock Up Today?
3M ago
VIR
Astellas Settles Myrbetriq Patent Disputes with Lupin and Zydus
PremiumCompany Announcements
Astellas Settles Myrbetriq Patent Disputes with Lupin and Zydus
3M ago
Astellas-Backed Bladder Cancer Trial Nears Key Data Moment After Study Completion
PremiumCompany AnnouncementsAstellas-Backed Bladder Cancer Trial Nears Key Data Moment After Study Completion
4M ago
ALPMF
Solid Near-Term Outperformance but Post-Xtandi Uncertainty Keeps Shares at Hold
Premium
Ratings
Solid Near-Term Outperformance but Post-Xtandi Uncertainty Keeps Shares at Hold
4M ago
Astellas Lifts FY2025 Outlook on Robust XTANDI and Mirabegron Demand
Premium
Company Announcements
Astellas Lifts FY2025 Outlook on Robust XTANDI and Mirabegron Demand
4M ago
ALPMF Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
ALPMF Upcoming Earnings Report: What to Expect?
4M ago
Astellas Targets Post‑Stroke Recovery With First‑in‑Human ASP2246 Study
PremiumCompany Announcements
Astellas Targets Post‑Stroke Recovery With First‑in‑Human ASP2246 Study
5M ago
ALPMF
Astellas Completes Key Menopause Drug Study in Japan, Setting Up Next Growth Phase for Fezolinetant
PremiumCompany Announcements
Astellas Completes Key Menopause Drug Study in Japan, Setting Up Next Growth Phase for Fezolinetant
5M ago
ALPMF
Astellas and Pfizer Unveil Breakthrough in Bladder Cancer Treatment
PremiumCompany Announcements
Astellas and Pfizer Unveil Breakthrough in Bladder Cancer Treatment
5M ago
Astellas Pharma Revises FY2025 Financial Forecasts Upward
PremiumCompany AnnouncementsAstellas Pharma Revises FY2025 Financial Forecasts Upward
7M ago
Astellas Pharma (ALPMF) Q2 Earnings Cheat Sheet
Premium
Pre-Earnings
Astellas Pharma (ALPMF) Q2 Earnings Cheat Sheet
7M ago
Astellas Pharma’s ASP4396 Study: A Potential Game-Changer for Solid Tumors
Premium
Company Announcements
Astellas Pharma’s ASP4396 Study: A Potential Game-Changer for Solid Tumors
7M ago
ALPMF

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >